ESTRO 2024 - Abstract Book

S788

Clinical - CNS

ESTRO 2024

propose an innovative approach to improve the efficacy of Hypofractionated Stereotactic Radiotherapy (HSRT) after HBO (HBO-RT) for the treatment of recurrent HGG (rHGG).

Material/Methods:

We enrolled 15 patients (aged >18 years) with diagnosis of rHGG. A total dose of 15-25 Gy was administered in daily 5-Gy fractions for 3-5 consecutive days after daily HBO. Each fraction was delivered up to maximum of 60 minutes after HBO.

Results:

Median follow-up from HBO-RT was 28.6 (range: 5.3-56.8). No patient was lost to follow-up.

Median progression-free survival (mPFS) for all patients was 3.2 months (95% CI: 1.34- 6.4 ), while 3-month, 6-month and 12 month PFS was 60% (95%CI: 31.8.4-79.7), 40% (95%CI: 16.5-62.8) and10.0 (0.8-33.5) , respectively. Median overall survival (mOS) of HBO-RT was 11.7 months (95% CI: 7.3-29.3), while 3-month, 6-month and 12 month OS was 100% , 93.3% (61.3-99.0) and 46.7 % (21.2-68.8). No acute or late neurologic toxicity >grade 2 (CTCAE version 4.3) was observed in 86.66% of patients. Two patients developed G3 Radionecrosis.

Conclusion:

HSRT delivered after HBO appears to be effective for the treatment of R-HGG. One of advantages of HBO-RT is the reduced overall treatment time (3-5 consecutive days).

Keywords: hypofractionated stereotactic radiotherapy, HBO

References:

Rey S, Schito L, Koritzinsky M, Wouters BG. Molecular targeting of hypoxia in radiotherapy. Adv Drug Deliv Rev (2017) 109:45 – 62. doi:10.1016/J.ADDR.2016.10.002

Jo J, Schiff D. Current Considerations in the Treatment of Grade 3 Gliomas. Curr Treat Options Oncol (2022) 23:1219 – 1232. doi:10.1007/s11864-022-01000-z

Alpuim Costa D, Sampaio-Alves M, Netto E, Fernandez G, Oliveira E, Teixeira A, Daniel PM, Bernardo GS, Amaro C. Hyperbaric Oxygen Therapy as a Complementary Treatment in Glioblastoma-A Scoping Review. Front Neurol (2022) 13:886603. doi:10.3389/fneur.2022.886603